Observational studies | Infection prevention studies | |||
---|---|---|---|---|
No intervention | Non-decontamination | Anti-septic | TAP ± PPAP/EAP | |
Study characteristics | ||||
Sources | ||||
Number of studiesa | 111 | 45 | 13 | 48 |
Origin from systematic reviewb | 46 | 38 | 7 | 38 |
North American ICUsc | 32 | 10 | 6 | 3 |
LOS > 7 days | 88 | 37 | 9 | 37 |
MV for > 48 h for < 90%d | 21 | 1 | 5 | 11 |
Trauma ICUse | 22 | 8 | 2 | 14 |
PPAP use in the control groupf | 0 | 0 | 1 | 8 |
Study publication year (range) | 1987–2014 | 1987–2017 | 2000–2018 | 1984–2018 |
Group characteristics | ||||
Numbers of patients per control group (median; IQR)g | 279 135–707 | 75 61–161 | 96 36–217 | 86 31–128 |
Prevention effect size (odds ratio; 95% CI; number of studies) | ||||
VAP | NA | 0.73; 0.66–0.80 (45) (see Fig S2) | 0.89; 0.72–1.11 (10) (see Fig S3) | 0.38; 0.33–0.44 (37)h (see Fig S4) |
Bacteremia | NA | 0.99; 0.71–1.39 (6) (see Fig S5) | 0.72; 0.66–0.79 (10) (see Fig S6) | 0.69; 0.62–0.76 (33)i (see Fig S7) |